Skip to main content
. 2021 Jul 22;11:15007. doi: 10.1038/s41598-021-94572-z

Figure 6.

Figure 6

C. butyricum upregulated IL-17A in the cLP to increase IgA production under CDI. (A) Experimental design of fidaxomicin and CBM 588 administration with/without anti-IL-17A antibody in 9- to 10-week-old ICR Swiss mice. (B) Assessment of C. difficile in feces at day 8 and 10. 1: combination (CBM 588 + fidaxomicin) group (Combination), 2: combination group + anti-IL-17A antibody. The testing detectable level is above 2.0 (log amount) per gram of feces, data shown as mean ± SD (n = 5–10 per group). (C) Tumor necrosis factor-α (TNF-α) and (D) Immunoglobrin A (IgA) protein concentrations in mice colon tissue detected at day 8. All values are mean ± SD (n = 5–10).